WO2004037771A1 - A method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methylcarbamate - Google Patents

A method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methylcarbamate Download PDF

Info

Publication number
WO2004037771A1
WO2004037771A1 PCT/CZ2003/000058 CZ0300058W WO2004037771A1 WO 2004037771 A1 WO2004037771 A1 WO 2004037771A1 CZ 0300058 W CZ0300058 W CZ 0300058W WO 2004037771 A1 WO2004037771 A1 WO 2004037771A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
ethyl
rivastigmine
solution
Prior art date
Application number
PCT/CZ2003/000058
Other languages
French (fr)
Inventor
Hana Stepankova
Josef Hajicek
Stanislav Simek
Original Assignee
Zentiva, A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, A.S. filed Critical Zentiva, A.S.
Priority to EA200500049A priority Critical patent/EA006967B1/en
Priority to DE60321030T priority patent/DE60321030D1/en
Priority to UAA200500538A priority patent/UA79972C2/en
Priority to EP03769173A priority patent/EP1556338B1/en
Priority to US10/523,927 priority patent/US7544840B2/en
Priority to AU2003277795A priority patent/AU2003277795A1/en
Publication of WO2004037771A1 publication Critical patent/WO2004037771A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the invention concerns a method of production of (-)-(S)-3-[l-(dimethylamino)ethy ⁇ ]phenyl- N-ethyl-N-methylcarbamate and of its hydrogentartrate.
  • I known under the INN name rivastigmine is described in CS patent application No. PV 1991- 4110 as a substance that induces selective inhibition of acetylcholinesterase activity in the brain. This quality along with good tolerance by the human organism, an option to serve in the form of tablets (oral efficiency) and a long-term effect predestines rivastigmine for treatment of disorders associated with the cholinergic system disorder - especially of Alzheimer's disease.
  • racemic 3-[l-(dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate (hereinafter racemic rivastigmine), as a substance with a possible activity against Alzheimer's disease, was described in EP patent 193 926.
  • the method of its production was based on reaction of m- hydroxyphenylethyl-dimethylamine of formula IV
  • the present invention consists in a method of production of (-)-(S)-3-[l- (dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate (rivastigmine) of formula II
  • the phenol of formula III is converted with a strong base in an inert solvent into the phenolate and it is reacted with the carbamoylhalide of formula VII.
  • hydrides of alkali metals such as sodium hydride, or alkyl lithium compounds such as butyl lithium
  • the inert solvent is preferably chosen from the group of dialkyl ethers such as tetrahydrofuran or 1,2-dimethoxyethan.
  • the racemic phenol of formula IV can be obtained by reductive amination of methoxyacetophenone of formula VI
  • the reductive amination is carried out by means of dimethylamine or its hydrochloride and a reduction agent, usually a hydride such as sodium borohydride.
  • the O-dealkylation agents can be selected from among strong acids, such as for example hydrobromic acid, or from among boron halides, such as boron bromide.
  • the present method makes it possible for obtaining the product of formula I in an especially high optical purity.
  • a reproduction of the method known so far, even with recrystallization, has not resulted in obtaining such high optical purity.
  • titanic isopropoxide is slowly (5 minutes) added under inert conditions (N 2 , argon) to a solution of 75.5 g of dimethylamine in 1.5 1 of ethanol cooled to 10 °C in a water-ice bath, which is placed in a 6-liter three-neck flask fitted with a KPG stirrer, inlet and outlet of the inert and a thermometer, and, finally, 148.4 g of 3-methoxyacetophenone (VI) are added (5 minutes).
  • the addition of isopropoxide is slightly exothermic.
  • the resulting temperature of the reaction mixture after addition reaches 35 °C.
  • the reaction mixture is then mixed at room temperature for 9 to 10 hours. During the reaction period, the mixture becomes slightly turbid.
  • reaction mixture thickens into a slurry and foams and it needs to be mixed very intensively.
  • the temperature is kept within the range from 25 °C to 30 °C by mild cooling with ice. If the reaction mixture is overcooled below 20 °C a dense, difficult-to-mix foam forms upon addition of the borohydride.
  • the resulting white slurry is mixed for 10 to 12 hours at room temperature. Then, the supply of the inert is stopped and 800 ml of an aqueous solution of ammonium hydroxide (2:1) are slowly (over 10 minutes) poured into the reaction mixture.
  • the resulting mixture is mixed for 20 minutes.
  • the fine white crystals of the inorganic material are sucked away and well washed with methanol (ca 1 1).
  • the whole alcoholic fraction is evaporated from the filtrate in a rotary vacuum evaporator.
  • the evaporation residue is diluted with 1,000 ml of water and extracted with 3x 330ml of ethylacetate.
  • the combined ethylacetate extract are washed once with 100 ml of water and extracted with 3x 200 ml of hydrochloric acid (5:2).
  • the acidic aqueous extracts are combined and alkalized with 20% NaOH (ca 1 1) to pH 12 up to 14 and extracted with 3x 300 ml of ethylacetate.
  • the organic fraction is washed with 100 ml of water and 150 ml of brine. It is dried with anhydrous sodium sulfate. The desiccant is filtered off and the filtrate is evaporated to dryness in a rotary vacuum evaporator.
  • the solution becomes milky turbid and it is extracted with 3x 200 ml ethylacetate.
  • the ethylacetate fraction is shaken out lx with water, lx with brine and dried with anhydrous magnesium sulfate.
  • Activated carbon is added before filtering off the desiccant and the desiccant along with the carbon are filtered off.
  • the ethylacetate solution of compound (IV) is used for the next step.
  • 10-sulfonic acid (117.4 g (0.505 mol) in 250 ml of anhydrous ethanol), prepared in warm conditions, is added.
  • the solution is inoculated and left to stand in a refrigerator (+5 °C) overnight.
  • the precipitated crystals are sucked off through fritted glass and left to air dry overnight.
  • tetrahydrofuran 300 ml of tetrahydrofuran (THF) are placed in a 0.51-three-neck flask and sodium hydride as a 60% dispersion in oil (11.3 g) is added slowly under inert conditions (Ar or N 2 ) and stirring. A suspension develops, to which crystalline compound (III) (46.5 g, 0.281 mol) is added at room temperature. A solution of the phenolate forms, to which 35.7 g (0.281 mol) of carbamoylchloride are added dropwise over 10 minutes while slightly cooling down to 15 °C. The reaction is slightly exothermic. The rate of dropping is kept such that the temperature of the reaction mixture does not exceed 30 °C.
  • THF tetrahydrofuran
  • the organic layer is separated and extracted with 2x 50 ml of a 0.1 N NaOH solution.
  • the organic phase is extracted with 50 ml of water, dried with anhydrous magnesium sulfate, and concentrated in vacuo. 2.6 g of an oil are obtained (86.6% of the theoretical yield).
  • the solvent is evaporated in a rotary vacuum evaporator.
  • the evaporation residue is partitioned between 20 ml IN NaOH and 50 ml of ether.
  • the organic layer is separated and the aqueous fraction is shaken with additional 2x 20 ml of ether.
  • the combined ether layers are shaken with lx 20 ml water and lx 20 ml brine.
  • the organic fraction is dried over anhydrous sodium sulfate and concentrated in vacuo. 1.56 g of an oil are obtained (51.5% of the theoretical yield).
  • the obtained results differed according to the used method of resolving substance IV.
  • the method with 1 equivalent amount of (S)-(+)-camphor-10-sulfonic acid provided a total yield of 16.2 % based on compound IV and that with 0.6 equivalent provided a total yield of 19.5 % based on compound IV.

Abstract

The compound of formula (III), optionally its alkaline salt, is reacted with a compound of formula VII, wherein X is a leaving group, resulting in (S)-rivastigmine of formula II, which is then optionally converted into (S)-rivastigmine hydrogentartrade of formula I.

Description

A method of production of (-)-(S)-3-[l-(dimethylamino)ethyl]phenyl-N-ethyl-N- methylcarb amate
Technical Field
The invention concerns a method of production of (-)-(S)-3-[l-(dimethylamino)ethyι]phenyl- N-ethyl-N-methylcarbamate and of its hydrogentartrate.
Background Art
(-)-(S)-3-[l-(dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate tartrate of formula I
Figure imgf000003_0001
00"
I known under the INN name rivastigmine, is described in CS patent application No. PV 1991- 4110 as a substance that induces selective inhibition of acetylcholinesterase activity in the brain. This quality along with good tolerance by the human organism, an option to serve in the form of tablets (oral efficiency) and a long-term effect predestines rivastigmine for treatment of disorders associated with the cholinergic system disorder - especially of Alzheimer's disease.
Racemic 3-[l-(dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate (hereinafter racemic rivastigmine), as a substance with a possible activity against Alzheimer's disease, was described in EP patent 193 926. The method of its production was based on reaction of m- hydroxyphenylethyl-dimethylamine of formula IV
Figure imgf000003_0002
IV
with a carbamoylhalide of formula VI
Figure imgf000004_0001
VII wherein X represents a leaving group.
Methods for producing these racemic intermediates were described in earlier literature, but no possibility of converting the same into optically active enantiomers is mentioned anywhere.
In the cited CS application PV 1991-4110, it is demonstrated using both „in vitro" and „in vivo" experiments that the optically active (S)-isomer is a much more effective and selective inhibitor of acetylcholinesterase than a racemic mixture of the two isomers.
In the cited application, there is described a method of preparation of rivastigmine from the racemic mixture consisting in preparation of diastereoisomeric salts with (+)-O,O-di-(p- toluyl)-D-tartaric acid and their separation by crystallization. The (S)-enantiomer of rivastigmine was released from the obtained salt with a sodium hydroxide solution.
The basic technological disadvantage of this procedure is that optical resolution is performed only in the final stage of synthesis. This means that at least 50% of the prepared racemic rivastigmine (i.e. the (R)-enantiomer)) represents a useless waste; in fact, this waste is much bigger since optical resolution never separates enantiomers quantitatively. This makes the total yield of the synthesis low and the whole process is economically disadvantageous. Another drawback consists in distribution of the losses into individual steps. In general, the losses in a more advanced intermediate are more cost consuming than those in the initial steps.
As it has turned out in testing said procedure, resolution does not result in achieving satisfactory optical purity and the substance has to be additionally recrystallized (cf. Reference Example 1). The necessity of using the expensive and carcinogenic substance of formula VII (mostly specifically N-ethyl-N-methylcarbamoyl chloride) in an about 300% excess is another drawback
Resolution in an earlier stage of the synthesis appears, at first sight, as desirable, but far from being feasible. There remains the question whether it is possible to obtain enantiomerically pure intermediates and, especially, whether these products can be used for further synthesis without being subject to racemization. The necessity of recrystallization would cast doubts on advantageousness of such procedure.
It has now turned out that optically resolving the intermediate products (i.e. performing the operation in an earlier stage of production) and performing the final step with an optically active substance, permits to obtain a very good yield of (S)-rivastigmine with retaining high analytic purity.
Disclosure of Invention
The present invention consists in a method of production of (-)-(S)-3-[l- (dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate (rivastigmine) of formula II
Figure imgf000005_0001
or of its hydrogentartrate of formula I
Figure imgf000005_0002
starting from the optically active phenol of formula III
Figure imgf000006_0001
which is, optionally in the form of its alkali salt, reacted with a carbamoylhalide of formula VII
Figure imgf000006_0002
VII wherein X is a leaving group.
The resulting compound of formula II
Figure imgf000006_0003
is converted, by reacting with tartaric acid, into the respective salt of formula I.
Advantageously, the phenol of formula III is converted with a strong base in an inert solvent into the phenolate and it is reacted with the carbamoylhalide of formula VII.
As the strong base, hydrides of alkali metals, such as sodium hydride, or alkyl lithium compounds such as butyl lithium, can be used. The inert solvent is preferably chosen from the group of dialkyl ethers such as tetrahydrofuran or 1,2-dimethoxyethan.
The respective optically active phenol of formula III has not been described yet and it can be obtained by resolving the racemic phenol of formula IV
Figure imgf000007_0001
IV by reacting with an optically active acid, crystallizing the respective diastereόisomer and subsequently isolating the optically active phenol III.
The racemic phenol of formula IV can be obtained by reductive amination of methoxyacetophenone of formula VI
Figure imgf000007_0002
and subsequent O-dealkylation of the compound of formula V
Figure imgf000007_0003
The reductive amination is carried out by means of dimethylamine or its hydrochloride and a reduction agent, usually a hydride such as sodium borohydride.
The O-dealkylation agents can be selected from among strong acids, such as for example hydrobromic acid, or from among boron halides, such as boron bromide.
As is demonstrated in the examples of especially preferred embodiments, the present method makes it possible for obtaining the product of formula I in an especially high optical purity. A reproduction of the method known so far, even with recrystallization, has not resulted in obtaining such high optical purity.
It further results from comparison that use of the optically active compound of formula III results in lowering of the consumption of the expensive and carcinogenic N-ethyl-N- methylcarbamoylchloride (corresponding to general formula VII for X = CI) by 2/3. Examples
The subject matter of the invention is demonstrated in more detail in the following examples.
Example 1
Preparation of (S)-(-)-rivastigmine hydrogentartrate (I) (cf. Scheme 1)
Scheme 1
Figure imgf000008_0001
Resolving racemic compound (IX) with (+)-O,O'-ditoluyltartaric acid
49.6 g of racemic compound (IX) are dissolved in 100 ml of methanol and a solution of 75.8 g of (+)-O,O'-ditoluyltartaric acid in 200 ml of methanol is added to the solution. 150 ml of water are added stepwise to the clear solution, which is being mixed. The solution becomes turbid and starts to crystallize under cold conditions. 81.3 g of the desired salt in the form of white crystals with m.p. = 145-147 °C are obtained. The mentioned amount of the first fraction of crystals is recrystallized from a mixture of 200 ml of methanol and 100 ml of water. The second fraction of crystals (49.6 g, m.p.= 155-156°C) is obtained which is again recrystallized from the mixture (methanol : water (2:1), 200 ml). 39.0 g of the third fraction is obtained with m.p.= 159-162 °C. It is recrystallized from 150 ml of the mentioned mixture of solvents and the fourth final fraction of crystals is isolated (33.0 g, m.p.= 156-7 °C), which is Releasing the base (II)
The salt of S-(-)-rivastigmine (H) with (+)-O,O'-ditoluyltartaric acid (33.0 g) is slowly added to the well mixed mixture of 150 ml of dichloromethane and 150 ml of IN NaOH solution. After all the solids are dissolved, the layers are separated; the dichloromethane layer is extracted twice with 100 ml of water, dried with magnesium sulfate. The solvent is evaporated in vacuo and the evaporation residue is distilled under vacuum (b.p.= 135-8 °C, 40 Pa). 10.72 g of a colorless oil are obtained, which is 85% of the theoretical yield ([α]o = -24.5° ; c=3.5, methanol).
Preparation of (S)-(+)-rivastigmine hydrogentartrate (I)
8.86 g of the base (II) and 5.31 g of L-(+)-tartaric acid are dissolved under warm conditions and stirring in 20 ml of ethanol and the clear solution is precipitated with addition of ethylacetate (250 ml). The resulting mixture is left to cool down to +5 °C. The precipitated crystals are sucked away and washed with ethylacetate. 9.7 g of desired rivastigmine hydrogentartrate (I) results (i.e., 68.4 % of the theoretical yield) with m.p.= 124-126 °C. The contents of the undesired (R)-enantiomer in this fraction was 1 % (as determined by capillary electrophoresis).
0.3 g of the hydrogentartrate were recrystallized from a mixture ethanol/ethylacetate in the above specified manner and 0.24 g of a recrystallized fraction (I) were obtained (80 %). The contents of the undesired (R)-enantiomer has decreased to 0.69 % (capillary electrophoresis).
A total yield, based on the starting material (IV), of 12.5 % has been obtained.
Example 2
Preparation of (S)-(+)-rivastigmine hydrogentartrate (I) (cf. Scheme 2)
Scheme 2
Figure imgf000010_0001
Preparation of [l-(3-methoxyphenyl)ethyl]dimethylamine (V) according to Literature 2
0.5 1 of titanic isopropoxide is slowly (5 minutes) added under inert conditions (N2, argon) to a solution of 75.5 g of dimethylamine in 1.5 1 of ethanol cooled to 10 °C in a water-ice bath, which is placed in a 6-liter three-neck flask fitted with a KPG stirrer, inlet and outlet of the inert and a thermometer, and, finally, 148.4 g of 3-methoxyacetophenone (VI) are added (5 minutes). The addition of isopropoxide is slightly exothermic. The resulting temperature of the reaction mixture after addition reaches 35 °C. The reaction mixture is then mixed at room temperature for 9 to 10 hours. During the reaction period, the mixture becomes slightly turbid. After said period, 56.6 g of sodium borohydride are slowly and carefully added to the reaction mixture. The duration of this addition is about 2 hours. The reaction mixture thickens into a slurry and foams and it needs to be mixed very intensively. The temperature is kept within the range from 25 °C to 30 °C by mild cooling with ice. If the reaction mixture is overcooled below 20 °C a dense, difficult-to-mix foam forms upon addition of the borohydride. After the borohydride is added, the resulting white slurry is mixed for 10 to 12 hours at room temperature. Then, the supply of the inert is stopped and 800 ml of an aqueous solution of ammonium hydroxide (2:1) are slowly (over 10 minutes) poured into the reaction mixture. The resulting mixture is mixed for 20 minutes. The fine white crystals of the inorganic material are sucked away and well washed with methanol (ca 1 1). The whole alcoholic fraction is evaporated from the filtrate in a rotary vacuum evaporator. The evaporation residue is diluted with 1,000 ml of water and extracted with 3x 330ml of ethylacetate. The combined ethylacetate extract are washed once with 100 ml of water and extracted with 3x 200 ml of hydrochloric acid (5:2). The acidic aqueous extracts are combined and alkalized with 20% NaOH (ca 1 1) to pH 12 up to 14 and extracted with 3x 300 ml of ethylacetate. The organic fraction is washed with 100 ml of water and 150 ml of brine. It is dried with anhydrous sodium sulfate. The desiccant is filtered off and the filtrate is evaporated to dryness in a rotary vacuum evaporator. The crude product is distilled and ca 60 % of the desired product in the form of a colorless oil are obtained, b.p .= 68 °C at 400 Pa, 108 °C at 800 Pa
Preparation of 3-(l-dimethylaminoethyl)phenol (IV) according to Literature 3
94 g of [l-(3-methoxyphenyl)ethyl]dimethylamine (V) are dissolved in 285 ml of azeotropic hydrobromic acid and the resulting solution is refluxed under stirring using a reflux condenser for 12 hours (bath temperature 145-150 °C). During boiling, the reaction mixture darkens. The solution is then left to cool down to room temperature. Excess hydrobromic acid is evaporated using a rotary vacuum evaporator and the evaporation residue is dissolved in 200 ml of water. The solution is extracted with 3x 100 ml ethylacetate. The aqueous fraction is then gradually alkalized with the saturated solution of sodium carbonate with constant stirring (foam creation). The solution becomes milky turbid and it is extracted with 3x 200 ml ethylacetate. The ethylacetate fraction is shaken out lx with water, lx with brine and dried with anhydrous magnesium sulfate. Activated carbon is added before filtering off the desiccant and the desiccant along with the carbon are filtered off. The ethylacetate solution of compound (IV) is used for the next step.
Preparation of S-(-)-3-(l-dimethylamino)phenol (III)
Resolving compound (IV) with an 1 equivalent amount of S-(+)-camphor-10-sulfonic acid
A solution of compound (IV) in ethylacetate (0.505 mol)* in 500 ml of ethylacetate) is introduced into a 1 -liter round flask with a magnetic stirrer and a solution of S-(+)-camphor-
10-sulfonic acid (117.4 g (0.505 mol) in 250 ml of anhydrous ethanol), prepared in warm conditions, is added. The solution is inoculated and left to stand in a refrigerator (+5 °C) overnight. The precipitated crystals are sucked off through fritted glass and left to air dry overnight.
1) 82.2 g of white crystals with m.p. = 165-171 °C are obtained, which are dissolved in 190 ml of absolute ethanol under reflux. 380 ml of ethylacetate are added under warm conditions and crystallization is performed according to the above-mentioned procedure.
2) 64.1 g of white crystals with m.p. = 174-176 °C are obtained, which are dissolved in 150 ml of ethanol (absol.) under reflux and 300 ml of ethylacetate are added under warm conditions.
3) 56.5 g of white crystals with m.p.= 177-179 °C are obtained, which are dissolved in 130 ml of ethanol (absol.) under reflux and 260 ml of ethylacetate are added under warm conditions.
4) 51.6 g of white crystals with m.p.= 179-181 °C are obtained; i.e. 25.7 % of the theoretical amount.
* the contents of compound (IV) was determined by titration Resolving compound (IV) with 0.6 equivalent amount of S-(+)-camphor-10-sulfonic acid
100 g (0.605 mol) of compound (IV) are dissolved in 600 ml of ethylacetate under stirring and reflux. A solution of S-(+)-camphor-10-sulfonic acid (84.3 g (0.363 mol) in 125 ml of anhydrous ethanol) is added under stirring at 70 °C. The solution is inoculated, left to cool down to room temperature under stirring, cooled down with brine to -10 up to -15°C and it is left to crystallize for at least 12 hours under exclusion of air humidity. The precipitated first fraction of crystals is sucked off and air dried.
1) 95.0 g of white crystals with m.p.=173-175 °C are obtained, which are dissolved in 175 ml of ethanol under stirring and reflux and 350 ml of ethylacetate are added at a temperature of the solution between 60-70 °C. The camphorsulfonate will start to crystallize and is left to crystallize at a temperature -5 up to -10 °C for at least 12 hours. The precipitated fraction is sucked off, washed with 2x 50 ml of ethylacetate and air dried.
2) 79.5 g of the second fraction with m.p. 176-178 °C are obtained, which are again recrystallized in a mixture of ethanol : ethylacetate (150 ml:300 ml) following the above specified procedure. After being washed with 2x 50 ml of ethylacetate, the product is dried freely.
3) 74.6 g of the third fraction with m.p =177-179 °C are obtained; i.e. 31.0 % of the theoretical yield.
Releasing (S)-(-)-3-(l-dimethylamino)phenol (III)
4 1 of water were introduced in a 10-1 thick-wall beaker with a KPG stirrer. 250 g of sodium carbonate were added and dissolved under stirring. Crystals of the camphorsulfonate (517.5 g) were added in parts under stirring. When about half of the total amount was added 2 liters of dichloromethane were added. The remainder of the camphorsulfonate was added under constant stirring. The addition period was about 0.5 hour. The resulting mixture was stirred for another 0.5 hour. Then, the layers were separated in a 10-liter separating funnel. The aqueous fraction was extracted with 2x 1.5 liter of dichloromethane. The combined organic fractions were extracted with 1.5 liter of water and dried with 600 g of anhydrous sodium sulfate. The desiccant was then filtered off and the filtrate was evaporated until dry. The resulting evaporation residue was then dried in a rotary vacuum evaporator until constant weight at 50 °C and 2,7 kPa. A white crystalline substance forms (187.0 g; 87%), which is used without purification in the next stage, [ ]o •= -55.7° ; c=1.55, methanol).
The contents of the undesired (R)-enantiomer < 0.4% - determined using GC in a chiral column.
Preparation of S-(-)-rivastigmine (II)
300 ml of tetrahydrofuran (THF) are placed in a 0.51-three-neck flask and sodium hydride as a 60% dispersion in oil (11.3 g) is added slowly under inert conditions (Ar or N2) and stirring. A suspension develops, to which crystalline compound (III) (46.5 g, 0.281 mol) is added at room temperature. A solution of the phenolate forms, to which 35.7 g (0.281 mol) of carbamoylchloride are added dropwise over 10 minutes while slightly cooling down to 15 °C. The reaction is slightly exothermic. The rate of dropping is kept such that the temperature of the reaction mixture does not exceed 30 °C. After all the agent is added, the cooling system is put aside and the reaction mixture is mixed for 2 hours at room temperature. Thereafter, THF is evaporated in a rotary vacuum evaporator. The evaporation residue is partitioned between 200 ml IN NaOH and 500 ml of ether. The organic layer is separated and the aqueous fraction is shaken with additional 2x 200 ml of ether. The combined ether layers are shaken out with lx 100 ml water and lx 50 ml brine. The organic fraction is dried over anhydrous sodium sulfate. The solvent is evaporated and the crude product is vacuum distilled. b.p. = 135-140 °C at 13 Pa 45.6 g of a colorless viscous oil are obtained, i.e. a 80.5% yield, content GC 99.6%
Preparation of S-(+)-rivastigmine hydrogentartrate (I)
45.6 g of S-(-)-rivastigmine and 27.4 g of L-(+)-tartaric acid are dissolved in 125 of anhydrous ethanol at 60-70 °C under stirring. At this temperature, 630 ml of ethylacetate are gradually added to the solution. The solution is left to cool down to room temperature and to crystallize at +5 °C for at least 12 hours. The precipitated white crystalline product is sucked off, washed with 100 ml of ethylacetate, and vacuum dried at 40 °C. 67.5 g of the desired product with m.ρ.=125-126 °C (i.e. 92.6 % of the theoretical yield). ([α]D = +5.5 ° ; c=5, ethanol). The contents of the undesired R-enantiomer was less than 0.2 % in the sample (capillary electrophoresis).
Preparation of S-(-)rivastigmine (II)
150 ml of diethylether are placed in a 0.51-three-neck flask and sodium hydride as a 60% dispersion in oil (0.48 g) is added slowly under inert conditions (Ar or N2) and stirring. A suspension develops, to which crystalline compound (III) (2.0 g, 0.012 mol) is added at room temperature. After stirring for one hour, a slightly turbid solution of the phenolate forms, to which 1.53 g (0.012 mol) of N-ethyl-N-methylcarbamoylchloride in 20 ml of ether are added dropwise at room temperature. The resulting reaction mixture is stirred at room temperature for 3 hours. Thereafter, it is diluted with 100 ml of water. The organic layer is separated and extracted with 2x 50 ml of a 0.1 N NaOH solution. The organic phase is extracted with 50 ml of water, dried with anhydrous magnesium sulfate, and concentrated in vacuo. 2.6 g of an oil are obtained (86.6% of the theoretical yield).
Preparation of S-(-)rivastigmine (II)
50 ml 1,2-dimethoxyethane are placed in a 0.251 round three-neck flask and compound (III) (2.0 g, 0.012 mol) is dissolved therein under stirring and under an inert (Ar or N ) at room temperature. Then, a 1.6M solution of n-butyllithium in hexane (7.5 ml) is added dropwise to the resulting solution. A slightly turbid solution of the phenolate develops, to which 1.53 g (0.012 mol) of N-ethyl-N-methylcarbamoylchloride in 20 ml of 1,2-dimethoxyethane are added dropwise at room temperature. The solvent is evaporated in a rotary vacuum evaporator. The evaporation residue is partitioned between 20 ml IN NaOH and 50 ml of ether. The organic layer is separated and the aqueous fraction is shaken with additional 2x 20 ml of ether. The combined ether layers are shaken with lx 20 ml water and lx 20 ml brine. The organic fraction is dried over anhydrous sodium sulfate and concentrated in vacuo. 1.56 g of an oil are obtained (51.5% of the theoretical yield).
Preparation of S-(+)-rivastigmine hydrogentartrate (I)
2.0 g of base (II) and 1.2 g of L-(+)-tartaric acid are dissolved in 5 ml of methanol at 60 °C. The clear solution is left to cool down to room temperature and it is gradually precipitated with acetone (ca 50 ml). The resulting mixture is left to crystallize at +5 °C overnight. The deposited crystals are sucked off using fritted glass and washed with acetone. They are dried in vacuo at 40 °C and 2.4 g of white crystals (80% of the theoretical yield) with m.p.= 123-5 °C are obtained.
The obtained results differed according to the used method of resolving substance IV. The method with 1 equivalent amount of (S)-(+)-camphor-10-sulfonic acid provided a total yield of 16.2 % based on compound IV and that with 0.6 equivalent provided a total yield of 19.5 % based on compound IV.
Literature:
1) Stedman E, Stedman E.: J.Chem.Soc. 613 (1929)
2) Bhattacharyya, Sukanta: J.Org.Chem. 60; 15; 4928-4929 (1995)
3) Stedman; Stedman: J. Chem. Soc. 613, (1929)
4) MacDonald J.; Stedman E. : J. Chem. Soc. 2513, (1932)

Claims

C L A I M S
1. A method of production of (-)-(S)-3-[l-(dimethylamino)ethyl]phenyl-N-ethyl-N- methylcarbamate, i.e. rivastigmine of formula II
Figure imgf000017_0001
or of its hydrogentartrate of formula I
Figure imgf000017_0002
characterized in that the compound of formula III
Figure imgf000017_0003
III optionally its alkali salt, is reacted with a compound of formula VII
Figure imgf000017_0004
VII wherein X is a leaving group, resulting in the compound of formula II, which is then optionally converted, by reacting with tartaric acid, into the compound of formula I.
2. The method according to claim 1 characterized in that the compound of formula III is converted, by reacting with a strong base, into an alkaline salt, which is subsequently reacted with the compound of formula VII.
3. The method according to claim 1 or 2 characterized in that the compound of formula III is obtained by transforming methoxyacetophenone of formula VI
Figure imgf000018_0001
VI into racemic amine of formula IV
Figure imgf000018_0002
IV
which is further resolved by reacting with an optically active acid, whereafter the desired respective diastereoisomer is crystallized and finally converted into the compound of formula III.
4. The optically active compound having absolute configuration (S) of formula III
Figure imgf000018_0003
PCT/CZ2003/000058 2002-10-24 2003-10-21 A method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methylcarbamate WO2004037771A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EA200500049A EA006967B1 (en) 2002-10-24 2003-10-21 A method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate
DE60321030T DE60321030D1 (en) 2002-10-24 2003-10-21 PROCESS FOR PREPARING (-) - (S) -3-E1- (DIMETHYLAMINO) ETHYLENE PHENYL-N-ETHYL-N-METHYL CARBAMATE
UAA200500538A UA79972C2 (en) 2002-10-24 2003-10-21 Method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methylcarbamate and hydrogen-tartrate thereof
EP03769173A EP1556338B1 (en) 2002-10-24 2003-10-21 A method of production of (-)-(s)-3- [1-(dimethylamino)ethyl] phenyl-n-ethyl-n-methylcarbamate
US10/523,927 US7544840B2 (en) 2002-10-24 2003-10-21 Method of production of (−)-(S)-3-[1-(dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate
AU2003277795A AU2003277795A1 (en) 2002-10-24 2003-10-21 A method of production of (-)-(s)-3-(1-(dimethylamino)ethyl)phenyl-n-ethyl-n-methylcarbamate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZPV-2002-3555 2002-10-24
CZ20023555A CZ293014B6 (en) 2002-10-24 2002-10-24 Process for preparing (-)-(S)-3-[1-(dimethylamino)ethyl]phenyl-N-ethyl-N-methyl carbamate

Publications (1)

Publication Number Publication Date
WO2004037771A1 true WO2004037771A1 (en) 2004-05-06

Family

ID=29751096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2003/000058 WO2004037771A1 (en) 2002-10-24 2003-10-21 A method of production of (-)-(s)-3-[1-(dimethylamino)ethyl]phenyl-n-ethyl-n-methylcarbamate

Country Status (9)

Country Link
US (1) US7544840B2 (en)
EP (1) EP1556338B1 (en)
AT (1) ATE395330T1 (en)
AU (1) AU2003277795A1 (en)
CZ (1) CZ293014B6 (en)
DE (1) DE60321030D1 (en)
EA (1) EA006967B1 (en)
UA (1) UA79972C2 (en)
WO (1) WO2004037771A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061446A2 (en) 2003-12-24 2005-07-07 Generics [Uk] Limited Processes for the preparation of aminoalkyl phenylcarbamates
WO2006048720A1 (en) * 2004-11-08 2006-05-11 Emcure Pharmaceuticals Limited An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
WO2006068386A1 (en) * 2004-12-23 2006-06-29 Dong Kook Pharm. Co., Ltd Synthetic method of phenylcarbamate derivative
WO2007014973A2 (en) 2005-08-04 2007-02-08 Interquim, S.A. Method of obtaining phenyl carbamates
WO2007025481A1 (en) * 2005-09-02 2007-03-08 Shanghai Aobo Bio-Pharmaceutical Technology Co., Ltd Process for preparing (s)-n-ethyl-n-methyl-3-[1-(dimethylamino) ethyl]-phenyl carbamate and tartrate thereof
WO2008020452A1 (en) * 2006-08-17 2008-02-21 Alembic Limited Improved process for the preparation of rivastigmine
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
WO2008110339A2 (en) * 2007-03-09 2008-09-18 Synthon B.V. Polymorphs of rivastigmine hydrogentartrate
EP1980552A2 (en) 2007-04-10 2008-10-15 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
US7531684B2 (en) 2006-09-29 2009-05-12 Synthon Bv Process for making aminoalkylphenyl carbamates and intermediates therefor
WO2009086705A1 (en) 2008-01-10 2009-07-16 Shanghai Institute Of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
US7767843B2 (en) 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2010099745A1 (en) * 2009-03-03 2010-09-10 江苏恩华药业股份有限公司 Preparation methods of rivastigmine and its intermediate
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2011070585A1 (en) * 2009-10-28 2011-06-16 Shodhana Laboratories Limited Processes for preparing rivastigmine, salts and intermediates thereof
CN102285904A (en) * 2011-07-11 2011-12-21 中国科学院成都生物研究所 Method for preparing rivastigmine
WO2011159910A2 (en) 2010-06-17 2011-12-22 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
WO2012155834A1 (en) 2011-05-18 2012-11-22 浙江海正药业股份有限公司 Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates
CN102898333A (en) * 2012-10-22 2013-01-30 哈药集团三精制药股份有限公司 Preparation method of rivastigmine tartrate
US8420846B2 (en) 2008-08-25 2013-04-16 Jubilant Life Sciences Limited Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
CN101613292B (en) * 2009-07-29 2013-05-22 上海医药集团股份有限公司 (S)-3-(1-dimethylaminoethyl)phenol preparation method
CN103896787A (en) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 Rivastigmine precursor [1-(3-methoxyphenyl)ethyl]dimethylamine preparation method
CN109507345A (en) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 The method of separating and assaying of rivastigmine intermediate and its impurity
US10882819B2 (en) 2018-09-26 2021-01-05 Cadila Corporate Campus Synthesis of novel intermediate(s) for preparing rivastigmine

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101580482B (en) * 2009-05-27 2014-04-23 沈阳药科大学 Method for preparing rivastigmine hydrogen tartrate and application thereof
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
CN105254513A (en) * 2015-10-29 2016-01-20 无锡福祈制药有限公司 Resolution method of (S)-3-[1-(dimethylamino) ethyl] phenol (III)
CN106565543B (en) * 2016-10-14 2018-06-22 昆明源瑞制药有限公司 A kind of preparation method of rivastigmine-hydrogentartrate
CN113461554A (en) * 2020-03-30 2021-10-01 北京泰德制药股份有限公司 Purification method of rivastigmine intermediate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193926A2 (en) * 1985-03-05 1986-09-10 Proterra Ag Phenyl carbamates
US5602176A (en) * 1987-03-04 1997-02-11 Sandoz Ltd. Phenyl carbamate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193926A2 (en) * 1985-03-05 1986-09-10 Proterra Ag Phenyl carbamates
US5602176A (en) * 1987-03-04 1997-02-11 Sandoz Ltd. Phenyl carbamate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN CHUNG-PIN, TETRAHEDRON LETTERS, vol. 32, no. 49, 1991, pages 7175 - 7178, XP009025296 *
CISZEWSKA GRAZYNA, J.LABELLED COMPD.RADIOPHARM., vol. 39, no. 8, 1997, pages 651 - 668, XP002269029 *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061446A3 (en) * 2003-12-24 2006-01-05 Generics Uk Ltd Processes for the preparation of aminoalkyl phenylcarbamates
WO2005061446A2 (en) 2003-12-24 2005-07-07 Generics [Uk] Limited Processes for the preparation of aminoalkyl phenylcarbamates
JP2012072171A (en) * 2004-11-08 2012-04-12 Emcure Pharmaceuticals Ltd Efficient production method of (s)-3-[(1-dimethylamino)ethyl]-phenyl-n-ethyl-n-methyl-carbamic acid
WO2006048720A1 (en) * 2004-11-08 2006-05-11 Emcure Pharmaceuticals Limited An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
KR101168211B1 (en) 2004-11-08 2012-07-25 엠큐어 파마슈티컬즈 리미티드 An efficient method for preparation of S-3-[1-dimethyl aminoethyl]-phenyl-N-ethyl-N-methyl-carbamate
JP2008519023A (en) * 2004-11-08 2008-06-05 エムキュア ファーマシューティカルズ リミテッド Efficient process for producing (S) -3-[(1-dimethylamino) ethyl] -phenyl-N-ethyl-N-methyl-carbamic acid
WO2006068386A1 (en) * 2004-12-23 2006-06-29 Dong Kook Pharm. Co., Ltd Synthetic method of phenylcarbamate derivative
WO2007014973A2 (en) 2005-08-04 2007-02-08 Interquim, S.A. Method of obtaining phenyl carbamates
ES2267399A1 (en) * 2005-08-04 2007-03-01 Ragactives, S.L. Method of obtaining phenyl carbamates
WO2007014973A3 (en) * 2005-08-04 2007-05-03 Ragactives Sl Method of obtaining phenyl carbamates
EP1939172A4 (en) * 2005-08-04 2011-03-23 Interquim Sa Method of obtaining phenyl carbamates
EP1939172A2 (en) * 2005-08-04 2008-07-02 Interquim, S.A. Method of obtaining phenyl carbamates
WO2007025481A1 (en) * 2005-09-02 2007-03-08 Shanghai Aobo Bio-Pharmaceutical Technology Co., Ltd Process for preparing (s)-n-ethyl-n-methyl-3-[1-(dimethylamino) ethyl]-phenyl carbamate and tartrate thereof
CN100391938C (en) * 2005-09-02 2008-06-04 上海奥博生物医药技术有限公司 Preparation method of phenyl (S)-N-ethyl-N-methyl-3-[1-(dimethyamino)ethyl]-amidoformate (I) and tartrate thereof (II)
US7767843B2 (en) 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2008020452A1 (en) * 2006-08-17 2008-02-21 Alembic Limited Improved process for the preparation of rivastigmine
US7683205B2 (en) 2006-08-17 2010-03-23 Alembic Limited Process for the preparation of Rivastigmine
US7531684B2 (en) 2006-09-29 2009-05-12 Synthon Bv Process for making aminoalkylphenyl carbamates and intermediates therefor
EA021049B1 (en) * 2007-01-04 2015-03-31 Крка, Товарна Здравил, Д. Д., Ново Место Process for producing a crystalline form i of rivastigmine hydrogentartrate
WO2008081041A2 (en) * 2007-01-04 2008-07-10 Krka, Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
WO2008081041A3 (en) * 2007-01-04 2008-09-18 Krka Tovarna Zdravil D D Novo Amorphous and crystalline forms of rivastigmine hydrogentartrate
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
WO2008110339A3 (en) * 2007-03-09 2009-01-22 Synthon Bv Polymorphs of rivastigmine hydrogentartrate
WO2008110339A2 (en) * 2007-03-09 2008-09-18 Synthon B.V. Polymorphs of rivastigmine hydrogentartrate
EP1980552A3 (en) * 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
EP1980552A2 (en) 2007-04-10 2008-10-15 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
US8013181B2 (en) 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2009086705A1 (en) 2008-01-10 2009-07-16 Shanghai Institute Of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
US8324429B2 (en) 2008-01-10 2012-12-04 Shanghai Institute Of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
US8420846B2 (en) 2008-08-25 2013-04-16 Jubilant Life Sciences Limited Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
CN101823970B (en) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 Synthetic method of rivastigmine and intermediates thereof
WO2010099745A1 (en) * 2009-03-03 2010-09-10 江苏恩华药业股份有限公司 Preparation methods of rivastigmine and its intermediate
CN101613292B (en) * 2009-07-29 2013-05-22 上海医药集团股份有限公司 (S)-3-(1-dimethylaminoethyl)phenol preparation method
WO2011070585A1 (en) * 2009-10-28 2011-06-16 Shodhana Laboratories Limited Processes for preparing rivastigmine, salts and intermediates thereof
WO2011159910A2 (en) 2010-06-17 2011-12-22 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
WO2012155834A1 (en) 2011-05-18 2012-11-22 浙江海正药业股份有限公司 Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates
US9353049B2 (en) 2011-05-18 2016-05-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates
CN102285904A (en) * 2011-07-11 2011-12-21 中国科学院成都生物研究所 Method for preparing rivastigmine
CN102898333A (en) * 2012-10-22 2013-01-30 哈药集团三精制药股份有限公司 Preparation method of rivastigmine tartrate
CN103896787A (en) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 Rivastigmine precursor [1-(3-methoxyphenyl)ethyl]dimethylamine preparation method
CN109507345A (en) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 The method of separating and assaying of rivastigmine intermediate and its impurity
CN109507345B (en) * 2017-09-15 2022-08-05 万特制药(海南)有限公司 Rivastigmine bitartrate intermediate and separation and determination method of impurities thereof
US10882819B2 (en) 2018-09-26 2021-01-05 Cadila Corporate Campus Synthesis of novel intermediate(s) for preparing rivastigmine

Also Published As

Publication number Publication date
CZ20023555A3 (en) 2004-01-14
DE60321030D1 (en) 2008-06-26
AU2003277795A1 (en) 2004-05-13
ATE395330T1 (en) 2008-05-15
CZ293014B6 (en) 2004-01-14
EP1556338B1 (en) 2008-05-14
US7544840B2 (en) 2009-06-09
US20060122417A1 (en) 2006-06-08
EP1556338A1 (en) 2005-07-27
EA200500049A1 (en) 2005-06-30
UA79972C2 (en) 2007-08-10
EA006967B1 (en) 2006-06-30

Similar Documents

Publication Publication Date Title
EP1556338B1 (en) A method of production of (-)-(s)-3- [1-(dimethylamino)ethyl] phenyl-n-ethyl-n-methylcarbamate
EP2455075B1 (en) Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
US8193391B2 (en) Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N-alkyl-3-phenylpropylamines
SK288384B6 (en) Derivatives of 3,3-diphenyl propylamine and process for their preparation
SK9392002A3 (en) Process of preparing tolterodine and analogues thereof as well as intermediates prepared in the process
EP2181980A1 (en) A process for the preparation of (R)-1-aminoindanes
IL112819A (en) Fluorinated 1-aminoindan compounds and a process for their preparation
JPH107624A (en) Dimethyl-(3-aryl-buto-3-enyl)-amino compound as pharmaceutically active substance
EP2403823B1 (en) Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process
US7649114B2 (en) Separation of stereoisomeric N,N-dialkylamino-2alkyl-3-hydroxy-3-phenylalkanes
EP1927585A2 (en) Method of obtaining 3,3-diphenylpropylamines
AU2011222644A1 (en) Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
US7683205B2 (en) Process for the preparation of Rivastigmine
WO2007026373A2 (en) Process for preparing rivastigmine
WO2010046360A1 (en) Process for the preparation of substantially optically pure repaglinide and precursors thereof
EP1939172B1 (en) Method of obtaining phenyl carbamates
WO2012025941A2 (en) Processes for the preparation of fesoterodine
CZ296345B6 (en) Process for preparing (R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropylamine hydrochloride (atomoxetine)
EP1698615A1 (en) Method of obtaining tolterodine
KR100918692B1 (en) Method of preparing racemic toterodine, intermediate of racemic tolterodine, and method of preparing the same
WO2002076940A2 (en) Process for preparing arylpiperidine carbinol intermediates and derivatives
KR20090097835A (en) Intermediate of racemic tolterodine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003769173

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200500049

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2006122417

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10523927

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003769173

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10523927

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWG Wipo information: grant in national office

Ref document number: 2003769173

Country of ref document: EP